{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:18:45Z","timestamp":1789683525299,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-026-00814-4","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:23:30Z","timestamp":1784132610000},"page":"517-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2290-605X","authenticated-orcid":false,"given":"Adir","family":"Alper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Fagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avrohom","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamsa","family":"Murli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Faillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"814_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, de Boer IH, on behalf of the American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148:1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"key":"814_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, de Boer IH, Rangaswami J, on behalf of the American Heart Association. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148:1636\u201364. https:\/\/doi.org\/10.1161\/CIR.0000000000001186.","journal-title":"Circulation"},{"key":"814_CR3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff","year":"2014","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O\u2019Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PW. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129:S49\u201373. https:\/\/doi.org\/10.1161\/01.cir.0000437741.48606.98.","journal-title":"Circulation"},{"key":"814_CR4","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2014.2630","volume":"311","author":"P Muntner","year":"2014","unstructured":"Muntner P, Colantonio LD, Cushman M, Goff DC, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406\u201315. https:\/\/doi.org\/10.1001\/jama.2014.2630.","journal-title":"JAMA"},{"key":"814_CR5","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.jacc.2016.02.055","volume":"67","author":"JS Rana","year":"2016","unstructured":"Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67:2118\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.055.","journal-title":"J Am Coll Cardiol"},{"key":"814_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","volume":"64","author":"KN Karmali","year":"2014","unstructured":"Karmali KN, Goff DC, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1186.","journal-title":"J Am Coll Cardiol"},{"key":"814_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Munter P, Ballantyne CM, Brockman J, Coresh J, Pencina MJ. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation. 2024;149:430\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067626.","journal-title":"Circulation"},{"key":"814_CR8","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, Palaniappan LP, Sperling LS, Virani SS, Ho JE, Neeland IJ, Tuttle KR, Rajgopal Singh R, Elkind MSV, Lloyd-Jones DM, on behalf of the American Heart Association. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health. Circulation. 2023;148:1982\u20132004. https:\/\/doi.org\/10.1161\/CIR.0000000000001191.","journal-title":"Circulation"},{"issue":"10","key":"814_CR9","doi-asserted-by":"publisher","first-page":"e2438311","DOI":"10.1001\/jamanetworkopen.2024.38311","volume":"7","author":"B Scheuermann","year":"2024","unstructured":"Scheuermann B, Brown A, Colburn T, Hakeem H, Chow CH, Ade C. External validation of the American Heart Association PREVENT cardiovascular disease risk equations. JAMA Netw Open. 2024;7:e2438311. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.38311.","journal-title":"JAMA Netw Open"},{"key":"814_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.7326\/ANNALS-24-00074","volume":"177","author":"AMK Minhas","year":"2024","unstructured":"Minhas AMK, Virani SS, Michos ED, Mszar R, Cainzos-Achirica M, Blumenthal RS, Jones SR, Nasir K. Comparing cardiovascular risk classification of U.S. adults according to pooled cohort equations and PREVENT equations. Ann Intern Med. 2024;177:1444\u20138. https:\/\/doi.org\/10.7326\/ANNALS-24-00074.","journal-title":"Ann Intern Med"},{"key":"814_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamainternmed.2024.1302","volume":"184","author":"TS Anderson","year":"2024","unstructured":"Anderson TS, Wilson LM, Sussman JB. Atherosclerotic cardiovascular disease risk estimates using the predicting risk of cardiovascular disease events equations. JAMA Intern Med. 2024;184:963\u201370. https:\/\/doi.org\/10.1001\/jamainternmed.2024.1302.","journal-title":"JAMA Intern Med"},{"key":"814_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Gurbuz S, Coskun T, Haupt A, Milicevic Z. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402:472\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)01302-8.","journal-title":"Lancet"},{"key":"814_CR13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Konig M, Kazda C, Herber J, Coskun T, Milicevic Z. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2302392.","journal-title":"N Engl J Med"},{"key":"814_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Kwan TT, Konig M, Kazda C, Gurbuz S, Haupt A, Coskun T, Milicevic Z. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393:1065\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2505669.","journal-title":"N Engl J Med"},{"key":"814_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Guyatt GH, Li J, Liu R, Maloney A, Milicevic Z. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2511774. NEJMoa2511774.","journal-title":"N Engl J Med"},{"key":"814_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","volume":"24","author":"S Wharton","year":"2025","unstructured":"Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Haupt A, Milicevic Z. Treatment with orforglipron is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025;24:240. https:\/\/doi.org\/10.1186\/s12933-025-02781-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"814_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40842-025-00270-4","volume":"12","author":"A Alper","year":"2026","unstructured":"Alper A, Peleg G, Fagin A, Shah P, Chowdhury I, Faillace R. Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review. Cardiovasc Diabetol. 2026;12:9. https:\/\/doi.org\/10.1186\/s40842-025-00270-4.","journal-title":"Cardiovasc Diabetol"},{"key":"814_CR18","unstructured":"Mayer G (2024) preventr: an R package for calculating PREVENT cardiovascular risk scores. https:\/\/cran.r-project.org\/package=preventr"},{"key":"814_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"814_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jama.2024.12537","volume":"332","author":"JA Diao","year":"2024","unstructured":"Diao JA, Shi I, Murthy VL, Buckley TA, Patel CJ, Pierson E, Yeh RW, Kazi DS, Wadhera RK, Manrai AK. Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations. JAMA. 2024;332:989\u20131000. https:\/\/doi.org\/10.1001\/jama.2024.12537.","journal-title":"JAMA"},{"key":"814_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591\u2013602. https:\/\/doi.org\/10.1038\/nrcardio.2017.65.","journal-title":"Nat Rev Cardiol"},{"key":"814_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, M\u00f8ller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelorier J, Melenovsky V, Merkely B, Packer M, Sattar N, Sverdlov AL, Vinereanu D, Wachter R, Zannad F, Langkilde AM, Petersson M, Lam CSP, on behalf of the STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"key":"814_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, Gong M, Fletcher H, Gaspari F, Tatlisu MA, Remuzzi G, Heerspink HJL, Mahaffey KW, Perkovic V, Sattar N. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15\u201328. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"814_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001356","author":"WC Members","year":"2025","unstructured":"Members WC, Jones DW, Ferdinand KC, Goff DC, Hall JE, Himmelfarb CD, Juraschek SP, Moffett BS, Muntner P, Ogedegbe G, Talavera GA, Whelton PK, Wright JT, on behalf of the Joint Committee. 2025 AHA\/ACC guideline for the prevention, detection, evaluation and management of high blood pressure in adults. Circulation. 2025. https:\/\/doi.org\/10.1161\/CIR.0000000000001356.","journal-title":"Circulation"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-026-00814-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T08:52:17Z","timestamp":1788684737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-026-00814-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1007\/s40292-026-00814-4","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a post-hoc analysis of a published systematic review and meta-analysis and did not involve direct participation of human subjects or animals. Therefore, institutional review board approval and informed consent were not required.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}